慢性肝病治療藥物市場：依治療類型、疾病類型、分佈類型、地區：市場規模、份額、展望、機會分析，2023-2030

Chronic Liver Diseases Therapeutics Market, By Treatment Type, By Disease Type, By Distribution type, And By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年08月18日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球慢性肝病藥物市場規模為152億美元，預測期內（2023-2030年）複合年增長率為10.9%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	美國：152億美元
之前的數據	2018年至2021年	預測期	2023-2030
預測 2023-2030 年複合年增長率：	10.90%	2030年價值預測	美國：313億美元

肝臟是體內最大的固體器官，負責產生用於消化食物的膽汁、將食物轉化為能量以及體內足夠水平的化學物質，以儲存所有細胞和生物活動所需的營養。的角色，包括維持因此，肝功能不正常會導致甲型肝炎、B型肝炎、C型肝炎、原發性肝硬化、腫瘤等多種嚴重疾病。肝功能障礙的主要原因包括肥胖、過度飲酒和遺傳性疾病。肝病的治療包括抗病毒藥物、免疫抑制劑、疫苗、免疫球蛋白、皮質類固醇、標靶治療和化療。此外，慢性肝病還包括肝炎、自體免疫疾病、非酒精性脂肪肝（NAFLD）、癌症和遺傳性疾病。

市場動態

慢性肝病人口不斷增加，研發活動不斷增加，以開發治療肝病的新技術，以及市場上運營的主要公司採取合併、收購、聯盟和合作等無機增長策略。預計將在預測期內推動全球慢性肝病治療藥物市場成長的主要因素。例如，2022 年 12 月，專注於開髮用於治療肥胖和肝病的新型□療法的臨床階段生物製藥公司 Altimmune, Inc. 宣布，非酒精性脂肪肝疾病宣布了 24 項研究的積極頂線結果。Pemvidutide在該疾病中的為期一周（延長12 週）的試驗，證明了其顯著降低肝臟脂肪含量和肝炎的潛力。此外，2022 年 1 月，Madrigal Pharmaceuticals, Inc. 是一家臨床階段的生物製藥公司，致力於脂肪肝疾病的新療法。我們的主要臨床候選藥物 resmetilom 宣布了來自安慰劑對照、雙盲版本的 resmetilom 3 期 MAESTRO-NAFLD（非酒精性脂肪肝病）安全性研究的積極頂線臨床數據。

本次測試的主要特點

該報告對全球慢性肝病治療市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和複合年增長率（CAGR）。
它還闡明了各個細分市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景、主要參與者採取的競爭策略等的重要見解。
根據公司亮點、產品組合、主要亮點、績效和策略等參數對全球慢性肝病藥物市場的主要參與者進行了分析。
研究涵蓋的主要公司包括Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.。
全球慢性肝病治療藥物市場報告針對該行業的各個利益相關者，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
透過用於分析全球慢性肝病治療藥物市場的各種策略矩陣，將有助於利害關係人做出決策。

公司簡介
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

第10章

參考
調查方法

簡介目錄

Product Code: CMI4047

The global chronic liver diseases therapeutics market is estimated to be valued at US$ 15.2 billion in 2023 and is expected to exhibit a CAGR of 10.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 15.2 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	10.90%	2030 Value Projection:	US$ 31.3 Bn

Chronic Liver Diseases Therapeutics Market - IMG1

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

This report provides an in-depth analysis of the global chronic liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
- Antiviral drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Liver Diseases Therapeutics, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution type
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Chronic Liver Diseases Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Non-alcoholic Fatty Liver Disease (NAFLD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Chronic Liver Diseases Therapeutics Market, By Regions, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Astellas Pharma Inc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.